Ms. Christina Cameron reports

MEDICENNA TO PROVIDE CLINICAL UPDATE ON THE MDNA11 ABILITY-1 TRIAL AT THE UPCOMING AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING

Medicenna Therapeutics Corp. will present two posters at the American Association for Cancer Research Annual Meeting 2025 (AACR 2025) taking place April 25 to April 30, 2025 in Chicago, Ill.

The company will present an update from its phase 1/2 Ability-1 study evaluating MDNA11, the only long-acting, beta-enhanced not-alpha interleukin-2 (IL-2) super-agonist in clinical development. In addition, preclinical data for MDNA113, a novel first-in-class tumour-targeted and tumour-activated bifunctional anti-PD1-IL2 superkine, will also be presented at the conference.

Details for the abstracts and poster presentations are as follows:

Title:  interim results from the phase 1/2 Ability-1 study of a long-acting beta-enhanced not-alpha IL-2 superkine in patients with advanced solid tumours

Session title:  phase 0 and phase 1 clinical trials

Session date and time:  Monday, April 28, 2025; 9 a.m. to 12 p.m.

Location:  poster section 49

Poster board No.:  26

Abstract No.:  CT047

Title:  MDNA113: a tumour targeting and conditionally activated anti-PD1-IL2SK to enhance the therapeutic index

Session title:  T-cell engagers and novel antibody-based therapies

Session date and time:  Wednesday, April 30, 2025; 9 a.m. to 12 p.m.

Location:  poster section 40

Poster board No.:  16

Abstract No.:  7330

Following the conclusion of the AACR 2025 meeting, a copy of the posters will be available on the events and presentations page of Medicenna's website.

About Medicenna Therapeutics Corp.

Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 superkines, and first-in-class empowered superkines. Medicenna's long-acting IL-2 superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna's IL-4 empowered superkine, bizaxofusp (formerly MDNA55), has been studied in five clinical trials enrolling over 130 patients, including a phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained fast-track and orphan drug status from the FDA and FDA/EMA, respectively. Medicenna's early stage high-affinity IL-2beta biased IL-2/IL-15 super antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Medicenna's early stage BiSKITs (bifunctional superkine immunotherapies) and the T-MASK (targeted metalloprotease activated superkine) programs are designed to enhance the ability of superkines to treat immunologically cold tumours.

We seek Safe Harbor.